



# Determining an optimal schedule for pre-mixing chemotherapy drugs

Donald Richardson<sup>1</sup>, Amy Cohn PhD<sup>1</sup>, Alon Weizer MD<sup>2</sup>, Carolina Typaldos<sup>2</sup>, Kelly Procailo PharmD<sup>2</sup>  
University of Michigan<sup>1</sup>, University of Michigan Comprehensive Cancer Center<sup>2</sup>

## Introduction

Cancer is the second leading cause of death in the U.S., with ~1.6 million cases estimated for 2015. Over 50% of cases require chemotherapy treatment. Increasing demand has led to increased patient waiting times and overworked staff. What if we could reduce these burdens by pre-mixing Chemo drugs?

### What is Pre-mix?

Pre-mix is defined as the preparation of a drug before any patient is deemed ready to receive it. Generally, **pharmacies/cancer centers/institutions** do not pre-mix due to risk of wastage. In our model, we consider the tradeoff between waste cost and reduced patient waiting time.

## Probability of Wasting a Drug

Let:  $Prob(\text{Deferral or no show}) = p$

Assume:  $m_d =$  patients scheduled to receive drug  $d$  on a given day

$$Prob(\text{Wasting } n\text{th dose}) = \sum_{i=1}^n \binom{m_d}{m_d - i + 1} p^{m_d - i + 1} (1 - p)^{i-1}$$

What if the probability of deferral or no show depended on age, sex, treatment, type of cancer, etc.?

Let:  $Prob(\text{Deferral or no show of patient } i) = p_i$

Let:  $S_d =$  set of patients scheduled to receive drug  $d$

$\therefore S_d = \{1, 2, \dots, m_d\}$

$$Prob(\text{Wasting } 1^{\text{st}} \text{ dose}) = \prod_{i \in S_d} p_i$$

$$Prob(\text{Wasting } 2^{\text{nd}} \text{ dose}) = \sum_{i \in S_d} \left[ (1 - p_i) \prod_{j \in S_d \setminus i} (p_j) \right] + \prod_{i \in S_d} p_i$$

$Prob(\text{Wasting } 3^{\text{rd}} \text{ dose})$

$$= \sum_{i \in S_d} \sum_{j \in S_d \setminus i} \left[ (1 - p_i)(1 - p_j) \prod_{k \in S_d \setminus \{i, j\}} p_k \right] + \sum_{i \in S_d} \left[ (1 - p_i) \prod_{j \in S_d \setminus i} (p_j) \right] + \prod_{i \in S_d} p_i$$

## Model

### Parameters

$\Delta_d$ : the award or savings for mixing drug  $d$   
 $T$ : the total time units for the pre-mix period  
 $c_d$ : the cost of drug  $d$   
 $N_d$ : the number of doses needed for each drug based on the scheduled patients  
 $L$ : pre-mix capacity for any pre-mix period  
 $M$ : a very large number

### Sets

$D$ : set of drugs  $d$  (e.g. 50 mg of Taxotere)  
 $T$ : set of time units (each being 30 min)

### Variables

$x_{nt}^d = \begin{cases} 1 & \text{if pre-mixing the } n\text{th dose of drug } d \text{ at time } t \\ 0 & \text{otherwise} \end{cases}$   
 $y_n^d = \begin{cases} 1 & \text{if not pre-mixing the } n\text{th dose of drug } d \\ 0 & \text{otherwise} \end{cases}$

### Objective

Maximize the difference between expected reward and waste cost

$$\max \sum_d \sum_n \sum_t (\Delta_d - E_n^d[\text{waste cost}]) * x_{nt}^d, \quad \text{where } E_n^d[\text{waste cost}] = \sum_{w=1}^n c_d P_d(w)$$

### Constraints

$$\sum_t x_{nt}^d + y_n^d = 1 \quad \forall d, n \quad (1)$$

$$y_n^d \leq y_{n+1}^d \quad \forall d, n = 1, \dots, N_d - 1 \quad (2)$$

$$\sum_t t x_{nt}^d \leq \sum_t t x_{(n+1)t}^d + M * y_{n+1}^d \quad \forall d, n \quad (3)$$

$$\sum_d \sum_n x_{nt}^d \leq L \quad \forall t \quad (4)$$

$$\sum_t x_{nt}^d \leq 1 \quad \forall d, n \quad (5)$$

- (1) Relates the auxiliary variable to the decision variable
- (2) Ensures that subsequent doses are not pre-mixed if a previous one is not pre-mixed
- (3) Ensures the ordering of pre-mixed drugs
- (4) Cannot pre-mix more than L drugs during any period
- (5) Can only make the nth dose of a drug at most once

## Results

Suppose we have patients scheduled to receive 15 different drugs. Below is a sample of the drugs highlighting the variability in price.

Table 1: Give an explanation of this table!

Drug	Hang by time	Price	Currently pre-mixed?	Treatment for
Carboplatin	12 hrs	\$ 2.52	Yes	Cancer of the ovaries, head, and neck
Paclitaxel	12 hrs	\$ 4.10	Yes	Cancer in the lungs, ovary, or breast
Cyclophosphamide	12 hrs	\$ 879.00	Yes	Leukemia and lymphomas, and nephrotic syndrome
Folotyn	12 hrs	\$ 4,637.21	No	T-cell lymphoma
Adcetris	12 hrs	\$ 6,516.00	No	Treats Hodgkin's lymphoma and systemic anaplastic large cell lymphoma

Table 2: Give an explanation of this table!

Reward # of Doses	Scenario 1	Scenario 2	Scenario 3	Scenario 4	Scenario 5
$P_d(n)$	1 for all drugs	11.67 for all drugs	11.67 for all drugs	11.67 for all drugs	11.67 for all drugs
	2 for each drug	2 for each drug	2 for each drug	1-2 lower cost 3-5 higher cost	1-2 lower cost 3-5 higher cost
	$p=0.25$ for all drugs	$p=0.25$ for all drugs	inverse to cost of drug ranging from 0.02 to 0.30	$p=0.25$ for all drugs	inverse to cost of drug ranging from 0.02 to 0.30

Table 3: Give an explanation of this table!

Drugs	Cost	Scenario 1	Scenario 2	Scenario 3	Scenario 4	Scenario 5
A	\$ 1.61	2	2	2	2	—
B	\$ 2.52	1	2	2	2	1
C	\$ 4.10	1	2	2	1	—
D	\$ 6.80	1	1	1	1	1
E	\$ 16.56	—	1	1	1	—
F	\$ 83.40	—	—	—	—	—
G	\$ 91.54	—	—	—	—	—
H	\$ 155.56	—	—	—	—	—
I	\$ 367.02	—	—	—	—	—
J	\$ 698.60	—	—	—	—	1
K	\$ 879.00	—	—	—	1	2
L	\$ 1,158.84	—	—	—	—	1
M	\$ 2,389.39	—	—	—	—	—
N	\$ 4,637.21	—	—	—	—	—
O	\$ 6,516.00	—	—	—	—	2
TOTAL	—	5	8	8	8	8

## Future Work

### Static Model

- Include the hang-by time for each drug
- Include the preparation time for each drug
- Continue working with data collection to run logistical regression
- How to categorize various types of patients

### Dynamic Model

Goal: To find an optimal drug-mixing schedule throughout the day and update as we observe patient deferrals

## Acknowledgements

Thanks to our student collaborators: Pamela Martinez, Matt Rouhana, Ajaay Chandrasekaran, Jonathan Zhou, and Hassan Abbas

This research is generously supported by the Center for Healthcare Engineering and Patient Safety and the Rackham Merit Fellowship Program.

Do not set text/images lower than this.